The University of Chicago Header Logo

Hedy Kindler

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
Email
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    UG1CA233327     (KINDLER, HEDY L)Mar 6, 2019 - Feb 28, 2025
    NIH
    UG1 - NCTN (Network Lead)
    Role: Principal Investigator
    U10CA180836     (KINDLER, HEDY L)Apr 28, 2014 - Feb 28, 2019
    NIH
    NCI National Clinical Trials Network-Network Lead Academic Participating Sites
    Role: Principal Investigator
    R21CA140003     (SALGIA, RAVI)Mar 1, 2009 - Feb 28, 2012
    NIH
    Novel Targeted Therapy in Pancreatic Cancer
    Role: Co-Principal Investigator
    U10CA041287     (KINDLER, HEDY L)Sep 30, 1986 - Mar 31, 2015
    NIH
    Cancer and Leukemia Group B
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Shenouda M, Gudmundsson E, Li F, Straus CM, Kindler HL, Dudek AZ, Stinchcombe T, Wang X, Starkey A, Armato Iii SG. Convolutional Neural Networks for Segmentation of Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance). J Imaging Inform Med. 2024 Sep 12. PMID: 39266911.
      Citations:    Fields:    
    2. Kindler HL, Rosenthal A, Giroux DJ, Nowak AK, Billè A, Gill RR, Pass H, Rice D, Ripley RT, Wolf A, Blyth KG, Cedres S, Rusch V, members of the IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions, Kindler HL, Rosenthal A, Giroux DJ, Nowak AK, Billè A, Gill RR, Pass H, Rice D, Ripley RT, Wolf A, Blyth KG, Rusch V, Members of the IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Ins. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Nov; 19(11):1564-1577. PMID: 39181447.
      Citations: 1     Fields:    
    3. Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928. PMID: 39197359; PMCID: PMC11416719.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    4. Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-ß2 levels in metastatic colorectal cancer patients (Alliance). BMC Genomics. 2024 May 14; 25(1):473. PMID: 38745123; PMCID: PMC11092225.
      Citations:    Fields:    Translation:Humans
    5. Nowak AK, Giroux DJ, Eisele M, Rosenthal A, Bille A, Gill RR, Kindler HL, Pass HI, Rice D, Ripley RT, Wolf A, Friedberg J, Nishimura K, Rusch VW, Members of the Staging and Prognostic Factors Committee of the Advisory Boards and Participating Ins. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Sep; 19(9):1339-1351. PMID: 38734072.
      Citations:    Fields:    Translation:Humans
    6. Bille A, Ripley RT, Giroux DJ, Gill RR, Kindler HL, Nowak AK, Opitz I, Pass HI, Wolf A, Rice D, Rusch VW, Members of the Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institut. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Sep; 19(9):1326-1338. PMID: 38734073; PMCID: PMC11380593.
      Citations:    Fields:    Translation:Humans
    7. Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, Chitnis M, Roy A, Gilligan D, Kindler H, Papadatos-Pastos D, Ceresoli GL, Mansfield AS, Tsao A, O'Byrne KJ, Nowak AK, Steele J, Sheaff M, Shiu CF, Kuo CL, Johnston A, Bomalaski J, Zauderer MG, Fennell DA, ATOMIC-Meso Study Group. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024 Apr 01; 10(4):475-483. PMID: 38358753; PMCID: PMC10870227.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    8. Nowak AK, Opitz I, Pass HI, Gill RR, Giroux DJ, Eisele M, Rosenthal A, Kindler H, Wolf A, Ripley RT, Billé A, Rice D, Rimner A, de Perrot M, Rusch VW, members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Sep; 19(9):1310-1325. PMID: 38521202; PMCID: PMC11380601.
      Citations: 1     Fields:    Translation:Humans
    9. Bansal VV, Mitchell O, Drazer MW, Kindler HL, Turaga KK. ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma. Ann Surg Oncol. 2024 Jun; 31(6):3785-3786. PMID: 38502295.
      Citations:    Fields:    Translation:Humans
    10. Bansal VV, Mitchell O, Bregio C, Witmer HDD, Dhiman A, Godley FA, Ong C, Berger Y, Reddy B, Churpek JE, Drazer MW, Eng OS, Kindler HL, Turaga KK. ASO Visual Abstract: Venous Thromboembolism in Peritoneal Mesothelioma-Uncovering the Hidden Risk. Ann Surg Oncol. 2024 Mar 08. PMID: 38457102.
      Citations:    Fields:    
    11. Medved M, Witmer HDD, Dhiman A, Berger Y, Sherman SK, Hindi ES, Armato SG, Reiser IS, Oto A, Engelmann RM, Kindler HL, Oren NC, Harmath CB, Turaga KK. Implementation of a high-resolution, high-contrast magnetic resonance imaging protocol with extended delayed phases for peritoneal mesothelioma. Quant Imaging Med Surg. 2024 Mar 15; 14(3):2580-2589. PMID: 38545076; PMCID: PMC10963817.
      Citations:    
    12. Bansal VV, Mitchell O, Bregio C, Witmer HDD, Dhiman A, Godley FA, Ong C, Berger Y, Reddy B, Churpek JE, Drazer MW, Eng OS, Kindler HL, Turaga KK. Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk. Ann Surg Oncol. 2024 May; 31(5):3339-3349. PMID: 38372861.
      Citations:    Fields:    Translation:Humans
    13. Wolf AS, Eisele M, Giroux DJ, Gill R, Nowak AK, Bille A, Rice D, Ripley RT, Opitz I, Galateau-Salle F, Hasegawa S, Kindler HL, Pass HI, Rusch VW, Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma. J Thorac Oncol. 2024 Aug; 19(8):1242-1252. PMID: 38309456.
      Citations: 2     Fields:    Translation:Humans
    14. Symes E, Tjota M, Cody B, Kindler H, Mitchell O, Witmer H, Turaga K, Mueller J, Krausz T, Husain AN, Li H. Mesothelioma in situ of the peritoneum: report of three cases and review of the literature. Histopathology. 2024 Feb; 84(3):492-506. PMID: 38084880.
      Citations:    Fields:    Translation:Humans
    15. Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-ß2 levels in metastatic colorectal cancer patients (Alliance). medRxiv. 2023 Dec 04. PMID: 38106038; PMCID: PMC10723514.
      Citations:    
    16. Shenouda M, Gudmundsson E, Li F, Straus CM, Kindler HL, Dudek AZ, Stinchcombe T, Wang X, Starkey A, Armato SG. Convolutional Neural Networks for Segmentation of Malignant Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance). ArXiv. 2023 Nov 30. PMID: 38076518; PMCID: PMC10705569.
      Citations:    
    17. Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023 Nov; 29(11):2814-2824. PMID: 37857711; PMCID: PMC10667103.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    18. Abuzakhm SM, Sukrithan V, Fruth B, Qin R, Strosberg J, Hobday TJ, Semrad T, Reidy-Lagunes D, Kindler HL, Kim GP, Knox JJ, Kaubisch A, Villalona-Calero M, Chen H, Erlichman C, Shah MH. A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2023 11 01; 30(11). PMID: 37702588; PMCID: PMC10585708.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    19. Chen-Yost HI, Schulte JJ, Tjota MY, Gao G, Mitchell O, Kindler H, Segal J, Husain AN, Mueller J. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology. Am J Clin Pathol. 2023 09 01; 160(3):238-246. PMID: 37141416.
      Citations: 1     Fields:    Translation:Humans
    20. Wolf AS, Rosenthal A, Giroux DJ, Nowak AK, Bille A, de Perrot M, Kindler HL, Rice D, Opitz I, Rusch VW, Pass HI, Members of the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic, Advisory Board, and Participating Institutions. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma. J Thorac Oncol. 2023 12; 18(12):1689-1702. PMID: 37567386; PMCID: PMC11168491.
      Citations: 1     Fields:    Translation:Humans
    21. Mitchell OD, Gilliam K, Del Gaudio D, McNeely KE, Smith S, Acevedo M, Gaduraju M, Hodge R, Ramsland ASS, Segal J, Das S, Hathaway F, Bryan DS, Tawde S, Galasinski S, Wang P, Tjota MY, Husain AN, Armato SG, Donington J, Ferguson MK, Turaga K, Churpek JE, Kindler HL, Drazer MW. Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma. JAMA Netw Open. 2023 08 01; 6(8):e2327351. PMID: 37556141; PMCID: PMC10413174.
      Citations: 3     Fields:    Translation:Humans
    22. Rosenzweig A, Berlin J, Chari S, Kindler H, Matrisian L, Mayoral A, Mills J, Nissen N, Picozzi V, Zelada-Arenas F, Fleming J. Management of Patients With Pancreatic Cancer Using the "Right Track" Model. Oncologist. 2023 07 05; 28(7):584-595. PMID: 37043728; PMCID: PMC10322133.
      Citations: 6     Fields:    Translation:Humans
    23. Berger Y, Gadiraju M, Dhiman A, Gilliam K, Opalecky B, Chen H, Helgeson M, Eng OS, Husain AN, Drazer MW, Kindler HL, Churpek JE, Turaga KK. Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation. Cancer. 2023 07 15; 129(14):2152-2160. PMID: 37042570.
      Citations:    Fields:    Translation:Humans
    24. Kindler HL, Yoo HK, Hettle R, Cui KY, Joo S, Locker GY, Golan T. Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Cancer. 2023 05 01; 129(9):1411-1418. PMID: 36811344.
      Citations: 4     Fields:    Translation:Humans
    25. Drogan CM, Kindler HL, Gao G, Kupfer SS. Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma. JCO Precis Oncol. 2023 01; 7:e2200196. PMID: 36689696.
      Citations: 1     Fields:    Translation:Humans
    26. Dhiman A, Vining CC, Witmer HDD, Sood D, Shergill A, Kindler H, Roggin KK, Posner MC, Ahmed OS, Liauw S, Pitroda S, Liao CY, Karrison T, Weichselbaum R, Eng OS, Catenacci DVT, Turaga KK, Polite B. ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Dec; 29(Suppl 3):616-617. PMID: 35930113.
      Citations: 1     Fields:    Translation:CTClinical Trials
    27. Witmer HDD, Dhiman A, Giurcanu M, Eng OS, Eggener S, Kindler HL, Turaga KK. A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database. Urol Oncol. 2023 01; 41(1):52.e11-52.e20. PMID: 36319552.
      Citations:    Fields:    Translation:Humans
    28. Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, O'Reilly EM, Bordia S, McGuinness D, Cui K, Locker GY, Golan T, Tortora G, Algül H. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022 12 01; 40(34):3929-3939. PMID: 35834777; PMCID: PMC10476841.
      Citations: 42     Fields:    Translation:HumansCellsCTClinical Trials
    29. Lee S, Ma C, Zhang S, Ou FS, Bainter TM, Niedzwiecki D, Saltz LB, Mayer RJ, Hantel A, Benson A, Atienza D, Kindler H, Gross CP, Irwin ML, Meyerhardt JA, Fuchs CS, Whittom R. Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). Oncologist. 2022 06 08; 27(6):e494-e505. PMID: 35641198; PMCID: PMC9177101.
      Citations: 8     Fields:    Translation:Humans
    30. Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6). PMID: 35732350; PMCID: PMC9226983.
      Citations: 9     Fields:    Translation:HumansCellsPHPublic Health
    31. Carbone M, Pass HI, Ak G, Alexander HR, Baas P, Baumann F, Blakely AM, Bueno R, Bzura A, Cardillo G, Churpek JE, De Rienzo A, Emi M, Emri S, Fennell DA, Flores RM, Grosso F, Hayward NK, Hesdorffer M, Hoang CD, Johansson PA, Kindler HL, Kittaneh M, Krausz T, Mansfield A, Metintas M, Minaai M, Mutti L, Nielsen M, O'Byrne K, Pastorino S, Pentimalli F, de Perrot M, Pritchard A, Ripley RT, Robinson B, Rusch V, Taioli E, Takinishi Y, Tanji M, Tsao AS, Tuncer AM, Walpole S, Wolf A, Yang H, Yoshikawa Y, Zolondick A, Schrump DS, Hassan R, Dianzani I, Felley-Bosco E, Opitz I. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. J Thorac Oncol. 2022 07; 17(7):873-889. PMID: 35462085; PMCID: PMC9233126.
      Citations: 29     Fields:    Translation:Humans
    32. Kindler HL, Novello S, Bearz A, Ceresoli GL, Aerts JGJV, Spicer J, Taylor P, Nackaerts K, Greystoke A, Jennens R, Burgers JA, Santoro A, Serwatowski P, Ponce S, Van Meerbeeck JP, Nowak AK, Blumenschein G, Siegel JM, Kasten L, Walter AO, Childs BH, Elbi C, Hassan R, Fennell DA, Calabrò L, Cedrés S, Köchert K. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022 04; 23(4):540-552. PMID: 35358455; PMCID: PMC10512125.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    33. Carlson B, Harmath C, Turaga K, Kindler HL, Armato SG, Straus C. The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. Abdom Radiol (NY). 2022 05; 47(5):1725-1740. PMID: 35257201.
      Citations:    Fields:    Translation:Humans
    34. Van Blarigan EL, Ou FS, Bainter TM, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Hantel A, Benson AB, Atienza D, Messino M, Kindler HL, Venook AP, Ogino S, Sanoff HK, Giovannucci EL, Ng K, Meyerhardt JA. Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. JAMA Netw Open. 2022 02 01; 5(2):e220145. PMID: 35191970; PMCID: PMC8864503.
      Citations: 3     Fields:    Translation:Humans
    35. Cheng E, Ou FS, Ma C, Spiegelman D, Zhang S, Zhou X, Bainter TM, Saltz LB, Niedzwiecki D, Mayer RJ, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Giovannucci EL, Van Blarigan EL, Brown JC, Ng K, Gross CP, Meyerhardt JA, Fuchs CS, Whittom R. Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). J Clin Oncol. 2022 03 01; 40(7):740-751. PMID: 34995084; PMCID: PMC8887946.
      Citations: 15     Fields:    Translation:Humans
    36. Dhiman A, Vining CC, Witmer HDD, Sood D, Shergill A, Kindler H, Roggin KK, Posner MC, Ahmed OS, Liauw S, Pitroda S, Liao CY, Karrison T, Weichselbaum R, Polite B, Eng OS, Catenacci DVT, Turaga KK. Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Jan 05. PMID: 34988836; PMCID: PMC8730296.
      Citations:    Fields:    
    37. Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 Jan; 126(1):162. PMID: 34853435; PMCID: PMC8727676.
      Citations:    Fields:    
    38. Kindler HL. Systemic Therapy for Mesothelioma: Turning the Corner. JCO Oncol Pract. 2022 06; 18(6):e843-e845. PMID: 34932380.
      Citations: 1     Fields:    Translation:Humans
    39. Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, Lanis M, Belcaid Z, Smith KN, Balan A, White JR, Cherry C, Ashok Sivakumar IK, Shao XM, Chan HY, Singh D, Thapa S, Illei PB, Pardoll DM, Karchin R, Velculescu VE, Brahmer JR, Ramalingam SS. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021 11; 27(11):1910-1920. PMID: 34750557; PMCID: PMC8604731.
      Citations: 44     Fields:    Translation:HumansCellsCTClinical Trials
    40. Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 02; 126(2):265-274. PMID: 34616010; PMCID: PMC8770703.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    41. Quintanilha JCF, Wang J, Sibley AB, Xu W, Espin-Garcia O, Jiang C, Etheridge AS, Ratain MJ, Lenz HJ, Bertagnolli M, Kindler HL, Dickler MN, Venook A, Liu G, Owzar K, Lin D, Innocenti F. Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. Int J Cancer. 2022 01 15; 150(2):279-289. PMID: 34528705; PMCID: PMC8627468.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    42. Kindler HL. Understanding the new therapeutic options for mesothelioma. Lancet Oncol. 2021 10; 22(10):1353-1355. PMID: 34499875.
      Citations: 1     Fields:    Translation:Humans
    43. Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518. PMID: 34168049.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    44. Quintanilha JCF, Liu Y, Etheridge AS, Yazdani A, Kindler HL, Kelly WK, Nixon AB, Innocenti F. Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance). Angiogenesis. 2022 02; 25(1):47-55. PMID: 34028627; PMCID: PMC8611102.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    45. Lee S, Zhang S, Ma C, Ou FS, Wolfe EG, Ogino S, Niedzwiecki D, Saltz LB, Mowat RB, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Gross CP, Irwin ML, Fuchs CS, Mayer RJ, Whittom R, Meyerhardt JA. Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). JNCI Cancer Spectr. 2021 06; 5(3). PMID: 34104867; PMCID: PMC8178799.
      Citations: 3     Fields:    Translation:Humans
    46. Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Shapira-Frommer R, Gao B, Kao S, Matos I, Planchard D, Chatterjee A, Jin F, Norwood K, Kindler HL, Calabrò L. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med. 2021 06; 9(6):613-621. PMID: 33836153.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    47. Luke JJ, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L, Barlesi F, Cassier PA. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021 02; 9(2). PMID: 33608377; PMCID: PMC7898862.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    48. Liauw SL, Ni L, Wu T, Arif F, Cloutier D, Posner MC, Kozloff M, Kindler HL. A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses. J Gastrointest Oncol. 2020 Dec; 11(6):1399-1407. PMID: 33457009; PMCID: PMC7807259.
      Citations: 5     
    49. Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth DK, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HL. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325. PMID: 33234578; PMCID: PMC7858231.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    50. White MG, Schulte JJ, Xue L, Berger Y, Schuitevoerder D, Vining CC, Kindler HL, Husain A, Turaga KK, Eng OS. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer. 2021 02; 124(3):564-566. PMID: 33100328; PMCID: PMC7851380.
      Citations: 11     Fields:    Translation:HumansCells
    51. Chapel DB, Schulte JJ, Absenger G, Attanoos R, Brcic L, Butnor KJ, Chirieac L, Churg A, Hiroshima K, Hung YP, Kindler H, Krausz T, Marchevsky A, Mino-Kenudson M, Mueller J, Nabeshima K, Turaga K, Walts AE, Husain AN, Galateau-Sallé F. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol. 2021 02; 34(2):380-395. PMID: 33060816.
      Citations: 11     Fields:    Translation:HumansCells
    52. Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ, Marabelle A, Miller WH, Italiano A. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 10; 21(10):1353-1365. PMID: 32919526.
      Citations: 976     Fields:    Translation:HumansCTClinical Trials
    53. Sharma MR, Joshi SS, Kindler HL. 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Response. Clin Cancer Res. 2020 07 15; 26(14):3890. PMID: 32669272; PMCID: PMC7413824.
      Citations:    Fields:    Translation:Humans
    54. Dudek AZ, Wang X, Gu L, Duong S, Stinchcombe TE, Kratzke R, Borghaei H, Vokes EE, Kindler HL. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. Clin Lung Cancer. 2020 11; 21(6):553-561.e1. PMID: 32727707; PMCID: PMC7606734.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    55. Cheng E, Zhang S, Ou FS, Mullen B, Ng K, Saltz LB, Niedzwiecki D, Mayer RJ, Mowat RB, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Giovannucci EL, Van Blarigan EL, Meyerhardt JA, Fuchs CS, Whittom R. The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). Cancer Epidemiol Biomarkers Prev. 2020 08; 29(8):1692-1695. PMID: 32499312; PMCID: PMC7415738.
      Citations: 3     Fields:    Translation:Humans
    56. Hassan R, Blumenschein GR, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, Seward SM, Thomas A, Kim SK, Rajagopalan P, Walter AO, Laurent D, Childs BH, Sarapa N, Elbi C, Bendell JC. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. J Clin Oncol. 2020 06 01; 38(16):1824-1835. PMID: 32213105; PMCID: PMC7255978.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    57. O'Hara MH, Messersmith W, Kindler H, Zhang W, Pitou C, Szpurka AM, Wang D, Peng SB, Vangerow B, Khan AA, Koneru M, Wang-Gillam A. Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. J Pancreat Cancer. 2020; 6(1):21-31. PMID: 32219196; PMCID: PMC7097682.
      Citations: 20     
    58. Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, Locker GY, Goranova T, Schatz P, Liu YZ, Hall MJ, Hammel P. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. J Clin Oncol. 2020 05 01; 38(13):1442-1454. PMID: 32073954.
      Citations: 27     Fields:    Translation:Humans
    59. Catenacci DVT, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala MM, Narula S, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Peterson B, Moore K, Kipping-Johnson K, Markevicius U, Gordon B, Allen K, Racette C, Maron SB, Liao CY, Polite BN, Kindler HL, Turaga K, Prachand VN, Roggin KK, Ferguson MK, Posner MC. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290. PMID: 32058557.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    60. O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol. 2020 05 01; 38(13):1378-1388. PMID: 31976786; PMCID: PMC7193749.
      Citations: 142     Fields:    Translation:HumansCTClinical Trials
    61. Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019 Dec; 30(12):1959-1968. PMID: 31987299.
      Citations:    
    62. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012 Nov; 23(11):2834-2842. PMID: 32018736.
      Citations:    
    63. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall M, Park J, Hochhauser D, Arnold D, Oh D, Reinacher-Schick A, Tortora G, Algül H, O'Reilly E, McGuinness D, Cui K, Schlienger K, Locker G, Kindler H. Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial. Ann Oncol. 2019 Jul; 30 Suppl 4:iv152. PMID: 32085054.
      Citations:    
    64. Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T, POLO Investigators, Hammel P, Algül H. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019 12 01; 30(12):1959-1968. PMID: 31562758; PMCID: PMC6938600.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    65. Golan T, Locker GY, Kindler HL. Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply. N Engl J Med. 2019 10 10; 381(15):1492-1493. PMID: 31597029.
      Citations: 6     Fields:    Translation:HumansCells
    66. Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite BN, Kindler HL, Sharma MR. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24. PMID: 31558477; PMCID: PMC6942629.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    67. Nicholson AG, Sauter JL, Nowak AK, Kindler HL, Gill RR, Remy-Jardin M, Armato SG, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiol P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Roden A, Roggli V, Scherpereel A, Tazelaar H, Travis WD, Tsao MS, van Schil P, Weynand B, Lang-Lazdunski L, Cree I, Rusch VW, Girard N, Galateau-Salle F, Perol M, Tirode F, Vignaud JM. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020 01; 15(1):29-49. PMID: 31546041.
      Citations: 56     Fields:    Translation:Humans
    68. Tan YC, Srivastava S, Won BM, Kanteti R, Arif Q, Husain AN, Li H, Vigneswaran WT, Pang KM, Kulkarni P, Sattler M, Vaidehi N, Mambetsariev I, Kindler HL, Wheeler DL, Salgia R. EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. Oncogenesis. 2019 Sep 04; 8(9):49. PMID: 31484920; PMCID: PMC6726628.
      Citations: 15     
    69. Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731. PMID: 31470129.
      Citations: 4     Fields:    Translation:Humans
    70. Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC. Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497. PMID: 31418130; PMCID: PMC6868305.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    71. Innocenti F, Jiang C, Sibley AB, Denning S, Etheridge AS, Watson D, Niedzwiecki D, Hatch AJ, Hurwitz HI, Nixon AB, Furukawa Y, Kubo M, Crona DJ, Kindler HL, McLeod HL, Ratain MJ, Owzar K. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenet Genomics. 2019 08; 29(6):123-131. PMID: 30889042; PMCID: PMC6636684.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    72. Fennell DA, Taylor P, Gilligan D, Nakano T, Scherpereel A, Pavlakis N, van Meerbeeck JP, Aerts JGJV, Nowak AK, Kindler H, Baas P. Reply to K. Masuda et al. J Clin Oncol. 2019 09 01; 37(25):2294-2295. PMID: 31329517.
      Citations: 1     Fields:    Translation:Humans
    73. Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2019 10 01; 25(19):5787-5798. PMID: 31263030; PMCID: PMC8132300.
      Citations: 42     Fields:    Translation:HumansCellsCTClinical Trials
    74. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 07 25; 381(4):317-327. PMID: 31157963; PMCID: PMC6810605.
      Citations: 922     Fields:    Translation:HumansCTClinical Trials
    75. Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019 Sep 15; 25(18):5493-5502. PMID: 31126960; PMCID: PMC7376746.
      Citations: 124     Fields:    Translation:Humans
    76. van Brummelen EMJ, Levchenko E, Fennell DA, Kindler HL, Gadgeel S, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Dómine M, Viteri S, López PG, Trigo J. A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Invest New Drugs. 2020 04; 38(2):457-467. PMID: 31065954; PMCID: PMC6898757.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    77. Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, Gadiraju M, Panou V, Gao S, Mian I, Khan J, Raffeld M, Patel S, Xi L, Wei JS, Hesdorffer M, Zhang J, Calzone K, Desai A, Padiernos E, Alewine C, Schrump DS, Steinberg SM, Kindler HL, King MC, Churpek JE. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019 04 30; 116(18):9008-9013. PMID: 30975761; PMCID: PMC6500142.
      Citations: 63     Fields:    Translation:HumansCells
    78. Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Nolan L, Kindler H, Aerts JGJV, Cedrés S. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019 04 01; 37(10):790-798. PMID: 30785827.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    79. Morales-Oyarvide V, Yuan C, Babic A, Zhang S, Niedzwiecki D, Brand-Miller JC, Sampson-Kent L, Ye X, Li Y, Saltz LB, Mayer RJ, Mowat RB, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Wolpin BM, Meyerhardt JA, Fuchs CS, Ng K, Whittom R. Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). J Natl Cancer Inst. 2019 02 01; 111(2):170-179. PMID: 30726946; PMCID: PMC6376913.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    80. Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, Marsh R, Kozloff MF, Polite BN, Catenacci DVT, Kindler HL. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636. PMID: 30645764.
      Citations: 18     Fields:    Translation:Humans
    81. Li F, Ahmad M, Qayyum F, Straus CM, MacMahon H, Kindler H, Armato SG. Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma. Eur Radiol. 2019 Jun; 29(6):2981-2988. PMID: 30617480.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    82. Kindler HL. A Glimmer of Hope for Pancreatic Cancer. N Engl J Med. 2018 12 20; 379(25):2463-2464. PMID: 30575492.
      Citations: 22     Fields:    Translation:Humans
    83. Innocenti F, Jiang C, Sibley AB, Etheridge AS, Hatch AJ, Denning S, Niedzwiecki D, Shterev ID, Lin J, Furukawa Y, Kubo M, Kindler HL, Auman JT, Venook AP, Hurwitz HI, McLeod HL, Ratain MJ, Gordan R, Nixon AB, Owzar K. Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep. 2018 11 05; 8(1):16332. PMID: 30397360; PMCID: PMC6218528.
      Citations: 8     Fields:    Translation:Humans
    84. Hmeljak J, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M, Sanchez-Vega F, Galateau-Sallé F. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565. PMID: 30322867; PMCID: PMC6310008.
      Citations: 283     Fields:    Translation:Humans
    85. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667. PMID: 30266660.
      Citations: 46     Fields:    Translation:Humans
    86. Romero-Calvo I, Weber CR, Ray M, Brown M, Kirby K, Nandi RK, Long TM, Sparrow SM, Ugolkov A, Qiang W, Zhang Y, Brunetti T, Kindler H, Segal JP, Rzhetsky A, Mazar AP, Buschmann MM, Weichselbaum R, Roggin K, White KP. Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. Mol Cancer Res. 2019 01; 17(1):70-83. PMID: 30171177; PMCID: PMC6647028.
      Citations: 53     Fields:    Translation:HumansAnimals
    87. Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose B, Zhang SR, Weatherly M, Nelakuditi V, Knight Johnson A, Helgeson M, Fischer D, Desai A, Sulai N, Ritterhouse L, Røe OD, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Kindler HL, Churpek JE. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J Clin Oncol. 2018 10 01; 36(28):2863-2871. PMID: 30113886; PMCID: PMC6804864.
      Citations: 92     Fields:    Translation:Humans
    88. Innocenti F, Owzar K, Jiang C, Etheridge AS, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR, Gordân R. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272. PMID: 30107003; PMCID: PMC6091939.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    89. Guercio BJ, Zhang S, Niedzwiecki D, Li Y, Babic A, Morales-Oyarvide V, Saltz LB, Mayer RJ, Mowat RB, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Zoltick ES, Stampfer M, Ng K, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS, Whittom R. Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One. 2018; 13(7):e0199244. PMID: 30024889; PMCID: PMC6053135.
      Citations: 15     Fields:    Translation:Humans
    90. Gudmundsson E, Labby Z, Straus CM, Sensakovic WF, Li F, Rose B, Cunliffe A, Kindler HL, Armato SG. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. Eur Radiol. 2019 Feb; 29(2):682-688. PMID: 29967955.
      Citations: 5     Fields:    Translation:Humans
    91. Kindler HL, Rusch V, Bueno R, Ismaila N, Pass H, Sterman D, Hassan R. Reply to D. de Fonseka et al. J Clin Oncol. 2018 09 10; 36(26):2746-2747. PMID: 29902108.
      Citations:    Fields:    Translation:Humans
    92. Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Mowat RB, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Ng K, Meyerhardt JA, Whittom R. Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. JAMA Oncol. 2018 06 01; 4(6):783-790. PMID: 29710284; PMCID: PMC6145685.
      Citations: 80     Fields:    Translation:Humans
    93. Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Li Y, Zhang X, Ng K, Willett WC, Giovannucci EL, Fuchs CS, Meyerhardt JA, Whittom R. Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectr. 2018 Feb; 2(2):pky017. PMID: 29877501; PMCID: PMC5977856.
      Citations: 9     Fields:    
    94. Vigneswaran WT, Kircheva DY, Rodrigues AE, Watson S, Celauro AD, Rose B, Kindler HL, Husain AN. Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. World J Surg. 2018 04; 42(4):1036-1045. PMID: 28948332.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    95. Benjamin AJ, Buschmann MM, Zhang SQ, Wroblewski K, Kindler HL, Roggin KK, Dale W. The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer. J Geriatr Oncol. 2018 07; 9(4):367-372. PMID: 29534880.
      Citations: 3     Fields:    Translation:Humans
    96. Kindler HL, Ismaila N, Hassan R. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018 04; 14(4):256-264. PMID: 29517955.
      Citations: 11     Fields:    Translation:Humans
    97. Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS. Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2018 04 10; 36(11):1112-1120. PMID: 29489429; PMCID: PMC5891130.
      Citations: 32     Fields:    Translation:HumansPHPublic Health
    98. Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018 04 03; 19(4):316-327. PMID: 29303405; PMCID: PMC5902231.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    99. Van Blarigan EL, Fuchs CS, Niedzwiecki D, Ye X, Zhang S, Song M, Saltz LB, Mayer RJ, Mowat RB, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Meyerhardt JA, Whittom R. Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev. 2018 04; 27(4):438-445. PMID: 29358223; PMCID: PMC5939380.
      Citations: 33     Fields:    Translation:HumansAnimals
    100. Kindler HL, Ismaila N, Armato SG, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Sterman D, Thomas A, Hassan R. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 05 01; 36(13):1343-1373. PMID: 29346042; PMCID: PMC8058628.
      Citations: 146     Fields:    Translation:Humans
    101. O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018 04 01; 124(7):1374-1382. PMID: 29338080; PMCID: PMC5867226.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    102. Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018 01; 89:19-26. PMID: 29223478; PMCID: PMC7351022.
      Citations: 81     Fields:    Translation:HumansCTClinical Trials
    103. de W Marsh R, Talamonti MS, Baker MS, Posner M, Roggin K, Matthews J, Catenacci D, Kozloff M, Polite B, Britto M, Wang C, Kindler H. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362. PMID: 29044544; PMCID: PMC5890423.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    104. Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48. PMID: 28978556; PMCID: PMC5894850.
      Citations: 148     Fields:    Translation:Humans
    105. Maio M, Scherpereel A, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL, Calabrò L. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 09; 18(9):1261-1273. PMID: 28729154.
      Citations: 178     Fields:    Translation:HumansCTClinical Trials
    106. Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K, Whittom R. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol. 2017 Jun 01; 28(6):1359-1367. PMID: 28327908; PMCID: PMC5789809.
      Citations: 19     Fields:    Translation:Humans
    107. Wagner AJ, Kindler H, Gelderblom H, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P, Schöffski P. A phase II study of a human anti-PDGFRa monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Ann Oncol. 2017 03 01; 28(3):541-546. PMID: 28426120; PMCID: PMC5391707.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    108. Wang X, Wang X, Hodgson L, George SL, Sargent DJ, Foster NR, Ganti AK, Stinchcombe TE, Crawford J, Kratzke R, Adjei AA, Kindler HL, Vokes EE, Pang H. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist. 2017 02; 22(2):189-198. PMID: 28188257; PMCID: PMC5330706.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    109. Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br J Cancer. 2017 Mar 14; 116(6):697-702. PMID: 28183138; PMCID: PMC5355924.
      Citations: 40     Fields:    Translation:Humans
    110. Vigneswaran WT, Kircheva DY, Ananthanarayanan V, Watson S, Arif Q, Celauro AD, Kindler HL, Husain AN. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma. Ann Thorac Surg. 2017 Mar; 103(3):962-966. PMID: 27765170.
      Citations: 20     Fields:    Translation:HumansCells
    111. Kindler HL. The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. J Oncol Pract. 2016 10; 12(10):936-937. PMID: 27858567.
      Citations: 1     Fields:    Translation:Humans
    112. Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, McCaughan BC, Nakano T, Ruffini E, van Meerbeeck JP, Yoshimura M, IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions, Galateau-Sallé F. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2112-2119. PMID: 27687962.
      Citations: 71     Fields:    Translation:Humans
    113. Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, Rusch VW, Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions, Billé A. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2089-2099. PMID: 27687963.
      Citations: 60     Fields:    Translation:Humans
    114. Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, Opitz I, Call S, Hasegawa S, Kernstine K, Atinkaya C, Rea F, Nafteux P, Rusch VW, Mesothelioma Domain of the IASLC Staging and Prognostic Factors Committee, advisory boards and parti. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2100-2111. PMID: 27687964.
      Citations: 46     Fields:    Translation:Humans
    115. Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992. PMID: 27623107; PMCID: PMC5021085.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    116. Rusch VW, Gill R, Mitchell A, Naidich D, Rice DC, Pass HI, Kindler HL, De Perrot M, Friedberg J, Malignant Mesothelioma Volumetric CT Study Group. A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. Ann Thorac Surg. 2016 Oct; 102(4):1059-66. PMID: 27596916; PMCID: PMC5031145.
      Citations: 28     Fields:    Translation:Humans
    117. Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137. PMID: 27275632; PMCID: PMC5210022.
      Citations: 162     Fields:    Translation:HumansCTClinical Trials
    118. Lennon FE, Cianci GC, Kanteti R, Riehm JJ, Arif Q, Poroyko VA, Lupovitch E, Vigneswaran W, Husain A, Chen P, Liao JK, Sattler M, Kindler HL, Salgia R. Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Sci Rep. 2016 Apr 15; 6:24578. PMID: 27080907; PMCID: PMC4832330.
      Citations: 26     Fields:    Translation:HumansCells
    119. Jahan T, Hassan R, Alley E, Kindler H, Antonia S, Whiting C, Coussens L, Murphy AL, Thomas A, Brockstedt DG. 208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial. J Thorac Oncol. 2016 Apr; 11(4 Suppl):S156. PMID: 27198358.
      Citations:    
    120. LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL, Ko AH. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar; 45(3):370-5. PMID: 26390428; PMCID: PMC5908466.
      Citations: 110     Fields:    Translation:HumansCellsCTClinical Trials
    121. Kircheva DY, Husain AN, Watson S, Kindler HL, Durkin A, Vigneswaran WT. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016 Jun; 49(6):1642-7. PMID: 26802143.
      Citations: 11     Fields:    Translation:Humans
    122. Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, Zauderer MG, Lolkema MP, Apt D, Yeh RF, Fredrickson JO, Spoerke JM, Koeppen H, Ware JA, Lauchle JO, Burris HA, de Bono JS. Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 06 15; 22(12):2874-84. PMID: 26787751; PMCID: PMC4876928.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    123. Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92. PMID: 26527777; PMCID: PMC4678179.
      Citations: 260     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    124. Williams T, Duraid H, Watson S, Durkin A, Todd K, Kindler HL, Vigneswaran WT. Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly. Ann Thorac Surg. 2015 Nov; 100(5):1868-74. PMID: 26319490.
      Citations: 6     Fields:    Translation:Humans
    125. Guercio BJ, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Hu FB, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS. Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2015 Nov 01; 33(31):3598-607. PMID: 26282659; PMCID: PMC4622099.
      Citations: 30     Fields:    Translation:Humans
    126. Burkholder D, Hadi D, Kunnavakkam R, Kindler H, Todd K, Celauro AD, Vigneswaran WT. Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma. Ann Thorac Surg. 2015 May; 99(5):1775-80. PMID: 25827675.
      Citations: 9     Fields:    Translation:Humans
    127. Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P, Öhman R. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr; 16(4):447-56. PMID: 25800891.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    128. Armato SG, Li P, Husain AN, Straus C, Khanwalkar A, Kindler HL, Vigneswaran WT. Radiologic-pathologic correlation of mesothelioma tumor volume. Lung Cancer. 2015 Mar; 87(3):278-82. PMID: 25641271.
      Citations: 6     Fields:    Translation:Humans
    129. Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2015 May 10; 33(14):1551-6. PMID: 25488966; PMCID: PMC4417726.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    130. Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S, Alliance for Clinical Trials in Oncology. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336. PMID: 25432408; PMCID: PMC4271075.
      Citations: 18     Fields:    Translation:Humans
    131. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01; 20(23):5927-36. PMID: 25231400; PMCID: PMC4252585.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    132. Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014; 9(9):e105919. PMID: 25221930; PMCID: PMC4164360.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    133. Catenacci DV, Amico AL, Nielsen SM, Geynisman DM, Rambo B, Carey GB, Gulden C, Fackenthal J, Marsh RD, Kindler HL, Olopade OI. Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer. 2015 Apr 01; 136(7):1559-67. PMID: 25123297; PMCID: PMC4303936.
      Citations: 33     Fields:    Translation:HumansCells
    134. Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs C, Innocenti F, Venook AP, Alliance for Clinical Trials in Oncology. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). J Natl Cancer Inst. 2014 Aug; 106(8). PMID: 25099612; PMCID: PMC4155431.
      Citations: 23     Fields:    Translation:Humans
    135. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma S. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer. 2014 Sep; 85(3):429-34. PMID: 25047675.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    136. Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Whittom R. Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS One. 2014; 9(6):e99816. PMID: 24937507; PMCID: PMC4061031.
      Citations: 46     Fields:    Translation:Humans
    137. Corbin KS, Kindler HL, Liauw SL. Considering the role of radiation therapy for gastrointestinal stromal tumor. Onco Targets Ther. 2014; 7:713-8. PMID: 24872712; PMCID: PMC4026585.
      Citations: 14     
    138. Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS, Lockhart AC, Hsu CP, Baker NF, Galimi F, Beltran P, Tabernero J, Baselga J. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Target Oncol. 2015 Mar; 10(1):65-76. PMID: 24816908; PMCID: PMC4317391.
      Citations: 18     Fields:    Translation:HumansAnimalsCTClinical Trials
    139. Katz MH, Landry J, Kindler HL. Current controversies in the stage-specific multidisciplinary management of pancreatic cancer. Am Soc Clin Oncol Educ Book. 2014; e157-64. PMID: 24857097.
      Citations: 4     Fields:    Translation:Humans
    140. Ramsdale E, Polite B, Hemmerich J, Bylow K, Kindler HL, Mohile S, Dale W. The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study. J Am Geriatr Soc. 2013 Nov; 61(11):2043-4. PMID: 24219208.
      Citations: 6     Fields:    Translation:Humans
    141. Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI, Alliance for Clinical Trials In Oncology. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res. 2013 Dec 15; 19(24):6957-66. PMID: 24097873; PMCID: PMC4219241.
      Citations: 61     Fields:    Translation:Humans
    142. Jeon J, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Atienza D, Messino M, Kindler H, Venook A, Fuchs CS, Meyerhardt JA. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer. 2013 Dec; 12(4):233-8. PMID: 24035029; PMCID: PMC3818492.
      Citations: 16     Fields:    Translation:Humans
    143. Labby ZE, Straus C, Caligiuri P, MacMahon H, Li P, Funaki A, Kindler HL, Armato SG. Variability of tumor area measurements for response assessment in malignant pleural mesothelioma. Med Phys. 2013 Aug; 40(8):081916. PMID: 23927330; PMCID: PMC3739828.
      Citations: 6     Fields:    Translation:Humans
    144. Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Newick K, Heitjan DF, Langer CJ, McPherson JM, Montaner LJ, Albelda SM. Immunological effects of the TGFß-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology. 2013 Aug 01; 2(8):e26218. PMID: 24179709; PMCID: PMC3812201.
      Citations: 36     Fields:    
    145. Geynisman DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci DV, Polite BN, Rosenbaum C, Namakydoust A, Karrison T, Gajewski TF, Kindler HL. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. J Immunother Cancer. 2013; 1:8. PMID: 24829746; PMCID: PMC4019890.
      Citations: 20     Fields:    
    146. McCaffery I, Tudor Y, Deng H, Tang R, Suzuki S, Badola S, Kindler HL, Fuchs CS, Loh E, Patterson SD, Chen L, Gansert JL. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res. 2013 Aug 01; 19(15):4282-9. PMID: 23741071.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    147. Rusch VW, Kindler HL. MARS: a sense of perspective and an inconvenient truth. J Thorac Oncol. 2013 May; 8(5):e49-50. PMID: 23584306.
      Citations: 1     Fields:    Translation:Humans
    148. Labby ZE, Armato SG, Dignam JJ, Straus C, Kindler HL, Nowak AK. Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. J Thorac Oncol. 2013 Apr; 8(4):478-86. PMID: 23486268; PMCID: PMC3597989.
      Citations: 9     Fields:    Translation:Humans
    149. Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, Pisters PW, Posner MC, Berlin JD, Ahmad SA. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013 Aug; 20(8):2787-95. PMID: 23435609; PMCID: PMC5600517.
      Citations: 111     Fields:    Translation:Humans
    150. Kindler HL. Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book. 2013; 182-8. PMID: 23714495.
      Citations: 18     Fields:    Translation:Humans
    151. Labby ZE, Nowak AK, Dignam JJ, Straus C, Kindler HL, Armato SG. Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol. 2013 Apr; 24(4):999-1005. PMID: 23144443; PMCID: PMC3603437.
      Citations: 13     Fields:    Translation:Humans
    152. Labby ZE, Armato SG, Kindler HL, Dignam JJ, Hasani A, Nowak AK. Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012 Nov; 7(11):1728-34. PMID: 23059782; PMCID: PMC3473122.
      Citations: 8     Fields:    Translation:Humans
    153. Kindler HL. Robust data: the essential foundation of a revised staging system for pleural mesothelioma. J Thorac Oncol. 2012 Nov; 7(11):1623-4. PMID: 23059784.
      Citations: 5     Fields:    Translation:Humans
    154. Carey GB, Kazantsev S, Surati M, Rolle CE, Kanteti A, Sadiq A, Bahroos N, Raumann B, Madduri R, Dave P, Starkey A, Hensing T, Husain AN, Vokes EE, Vigneswaran W, Armato SG, Kindler HL, Salgia R. Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. BMJ Open. 2012; 2(5). PMID: 23103606; PMCID: PMC3488720.
      Citations: 3     Fields:    
    155. Kalari S, Moolky N, Pendyala S, Berdyshev EV, Rolle C, Kanteti R, Kanteti A, Ma W, He D, Husain AN, Kindler HL, Kanteti P, Salgia R, Natarajan V. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. PLoS One. 2012; 7(9):e45330. PMID: 23028939; PMCID: PMC3444486.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    156. Mollberg NM, Vigneswaran Y, Kindler HL, Warnes C, Salgia R, Husain AN, Vigneswaran WT. Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2012 Oct; 94(4):1086-92. PMID: 22921241.
      Citations: 17     Fields:    Translation:Humans
    157. Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80. PMID: 22831987; PMCID: PMC4319647.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    158. Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012 Sep; 77(3):567-71. PMID: 22770372.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    159. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012 Nov; 23(11):2834-2842. PMID: 22700995.
      Citations: 98     Fields:    Translation:HumansCTClinical Trials
    160. Cella D, Butt Z, Kindler HL, Fuchs CS, Bray S, Barlev A, Oglesby A. Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Qual Life Res. 2013 Jun; 22(5):1105-12. PMID: 22678353.
      Citations: 15     Fields:    Translation:Humans
    161. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE, Jänne PA. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15. PMID: 22665541; PMCID: PMC3397785.
      Citations: 69     Fields:    Translation:HumansCTClinical Trials
    162. Besier T, Pillhofer M, Botzenhart S, Ziegenhain U, Kindler H, Spangler G, Bovenschen I, Gabler S, Künster AK. Child Abuse and Neglect: Screening for Risks During the Perinatal Period. Geburtshilfe Frauenheilkd. 2012 May; 72(5):397-402. PMID: 25298543; PMCID: PMC4168323.
      Citations: 3     Fields:    
    163. Dudek AZ, Pang H, Kratzke RA, Otterson GA, Hodgson L, Vokes EE, Kindler HL, Cancer and Leukemia Group B. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr; 7(4):755-9. PMID: 22425926; PMCID: PMC3308128.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    164. Mollberg NM, Parsad NM, Armato SG, Vigneswaran J, Kindler HL, Sensakovic WF, Salgia R, Silverstein JC, Vigneswaran WT. Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. Int Surg. 2012 Jan-Mar; 97(1):65-70. PMID: 23102002; PMCID: PMC3723194.
      Citations: 1     Fields:    Translation:Humans
    165. Kindler HL. A New Direction for Pancreatic Cancer Treatment: FOLFIRINOX in Context. Am Soc Clin Oncol Educ Book. 2012; 232-7. PMID: 24451740.
      Citations: 2     Fields:    
    166. Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X, Green M, Vokes EE, Kindler HL. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun; 76(3):393-6. PMID: 22197613; PMCID: PMC4778731.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    167. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84. PMID: 22142827; PMCID: PMC3412624.
      Citations: 49     Fields:    Translation:Humans
    168. Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D, Cancer and Leukemia Group B. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage. 2012 Feb; 43(2):205-17. PMID: 22104618; PMCID: PMC3658140.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    169. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R, Brägelmann J. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46. PMID: 21543897; PMCID: PMC3149873.
      Citations: 51     Fields:    Translation:HumansCells
    170. Kindler HL. Surgery for mesothelioma? The debate continues. Lancet Oncol. 2011 Aug; 12(8):713-4. PMID: 21723780.
      Citations: 3     Fields:    Translation:Humans
    171. Roberts AS, Campa MJ, Gottlin EB, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM, Patz EF. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer. 2012 Jan 15; 118(2):571-8. PMID: 21713765; PMCID: PMC3184330.
      Citations: 10     Fields:    Translation:Humans
    172. Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S, Sleckman BG, Taber D, Vokes EE, Stadler WM, Kindler HL. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5. PMID: 21552992; PMCID: PMC4317401.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    173. Campbell NP, Kindler HL. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011 Feb; 32(1):102-10. PMID: 21500129.
      Citations: 36     Fields:    Translation:HumansPHPublic Health
    174. Catenacci DV, Kozloff M, Kindler HL, Polite B. Personalized colon cancer care in 2010. Semin Oncol. 2011 Apr; 38(2):284-308. PMID: 21421118; PMCID: PMC3065981.
      Citations: 20     Fields:    Translation:HumansCells
    175. Loganathan S, Kanteti R, Siddiqui SS, El-Hashani E, Tretiakova M, Vigneswaran H, Cervantes G, Natarajan V, Husain AN, Vokes EE, Kindler HL, Salgia R. Role of protein kinase C ß and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism. J Carcinog. 2011 Mar 03; 10:4. PMID: 21383961; PMCID: PMC3049271.
      Citations: 3     
    176. Kindler HL, Ioka T, Richel DJ, Bennouna J, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E, Létourneau R. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011 Mar; 12(3):256-62. PMID: 21306953.
      Citations: 181     Fields:    Translation:HumansCTClinical Trials
    177. Sensakovic WF, Armato SG, Straus C, Roberts RY, Caligiuri P, Starkey A, Kindler HL. Computerized segmentation and measurement of malignant pleural mesothelioma. Med Phys. 2011 Jan; 38(1):238-44. PMID: 21361192; PMCID: PMC3021556.
      Citations: 26     Fields:    Translation:Humans
    178. Sensakovic WF, Armato SG, Starkey A, Kindler HL, Vigneswaran WT. Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication. Acad Radiol. 2011 Mar; 18(3):294-8. PMID: 21145765; PMCID: PMC3075578.
      Citations: 3     Fields:    Translation:Humans
    179. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM, Cancer and Leukemia Group B. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15(12):1310-9. PMID: 21148613; PMCID: PMC3227926.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    180. Ocean AJ, Polite B, Christos P, Horvath L, Hamilton A, Matulich D, Chen HX, Sparano JA, Kindler HL. Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer. 2010 Dec; 9(5):290-6. PMID: 21208843; PMCID: PMC3623373.
      Citations: 3     Fields:    Translation:Humans
    181. Dubey S, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL, Jänne PA. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61. PMID: 20736856; PMCID: PMC3823555.
      Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
    182. Kindler H. [Screening for risk of child abuse and neglect. A practicable method?]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Oct; 53(10):1073-9. PMID: 20936452.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    183. Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, Vokes EE. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Feb; 30(1):382-6. PMID: 20803052; PMCID: PMC4319645.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    184. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22. PMID: 20606091; PMCID: PMC2917317.
      Citations: 383     Fields:    Translation:HumansCTClinical Trials
    185. Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, Kelsen DP. A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs. 2011 Dec; 29(6):1475-81. PMID: 20574790.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    186. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12. PMID: 19858396; PMCID: PMC2792952.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    187. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009 Sep; 136(3):888-896. PMID: 19736192.
      Citations: 50     Fields:    Translation:Humans
    188. Nimeiri HS, Singh DA, Kasza K, Taber DA, Ansari RH, Vokes EE, Kindler HL. The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2010 Dec; 28(6):854-8. PMID: 19669700; PMCID: PMC4635688.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    189. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009 Jun 20; 27(18):3007-13. PMID: 19364962; PMCID: PMC3646305.
      Citations: 137     Fields:    Translation:HumansCTClinical Trials
    190. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009 Apr 20; 27(12):2081-90. PMID: 19255316; PMCID: PMC4881753.
      Citations: 133     Fields:    Translation:Humans
    191. Tarver K, Kindler H, Lythall D. Extensive aortic dissection presenting as acute inferior myocardial infarction. BMJ Case Rep. 2009; 2009:bcr2006097444. PMID: 21687150; PMCID: PMC3105971.
      Citations:    Fields:    
    192. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34. PMID: 19228743; PMCID: PMC3147153.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    193. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. PMID: 19169683.
      Citations: 116     Fields:    Translation:HumansCTClinical Trials
    194. Kindler HL, Aklilu M, Nattam S, Vokes EE. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol. 2008 Dec; 31(6):553-6. PMID: 19060586.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    195. Faoro L, Loganathan S, Westerhoff M, Modi R, Husain AN, Tretiakova M, Seiwert T, Kindler HL, Vokes EE, Salgia R. Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8. PMID: 18765998; PMCID: PMC2605682.
      Citations: 4     Fields:    Translation:HumansCells
    196. Kindler HL. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol. 2008 Jun; 9(2-3):171-9. PMID: 18770046; PMCID: PMC2782121.
      Citations: 24     Fields:    Translation:Humans
    197. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15; 113(4):808-14. PMID: 18543326.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    198. Undevia SD, Innocenti F, Ramirez J, House L, Desai AA, Skoog LA, Singh DA, Karrison T, Kindler HL, Ratain MJ. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92. PMID: 18650079; PMCID: PMC2731567.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    199. Simon GR, Verschraegen CF, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL, Jänne PA. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008 Jul 20; 26(21):3567-72. PMID: 18640937.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    200. Kindler HL, Burris HA, Sandler AB, Oliff IA. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs. 2009 Feb; 27(1):75-81. PMID: 18618081.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    201. Wiebe L, Kasza KE, Maki RG, D'Adamo DR, Chow WA, Wade Iii JL, Agamah E, Stadler WM, Vokes EE, Kindler HL. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol. 2008 May 20; 26(15_suppl):10502. PMID: 27948416.
      Citations:    
    202. Jhawer MP, Kindler HL, Wainberg ZA, Hecht JR, Kerr RO, Ford JM, Henderson C, Mueller T, Keer HN, Shah MA. Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study. J Clin Oncol. 2008 May 20; 26(15_suppl):4572. PMID: 27948655.
      Citations:    
    203. Kindler HL, Gangadhar T, Karrison T, Hochster HS, Moore MJ, Micetich K, Sun W, Catenacci DV, Stadler WM, Vokes EE. Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC). J Clin Oncol. 2008 May 20; 26(15_suppl):4502. PMID: 27949226.
      Citations:    
    204. Kratzke RA, Wang X, Wong L, Kratzke MG, Green MR, Vokes EE, Vogelzang NJ, Kindler HL, Kern JA, Cancer and Leukemia Group B. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol. 2008 Apr; 3(4):417-21. PMID: 18379362.
      Citations: 5     Fields:    Translation:HumansCells
    205. Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H, Jänne PA. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008 Mar 20; 26(9):1465-71. PMID: 18349397.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    206. Armato SG, Entwisle J, Truong MT, Nowak AK, Ceresoli GL, Zhao B, Misri R, Kindler HL. Current state and future directions of pleural mesothelioma imaging. Lung Cancer. 2008 Mar; 59(3):411-20. PMID: 18061303.
      Citations: 10     Fields:    Translation:Humans
    207. Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64. PMID: 18008108.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    208. Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, Jani AB, Kindler HL, Mundt AJ, Roeske JC, Chmura SJ. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Apr 01; 70(5):1431-7. PMID: 17996390.
      Citations: 87     Fields:    Translation:Humans
    209. Tarver K, Kindler H, Lythall D. Extensive aortic dissection presenting as acute inferior myocardial infarction. Heart. 2007 Oct; 93(10):1225. PMID: 17890699; PMCID: PMC2000954.
      Citations: 2     Fields:    Translation:Humans
    210. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007 Oct 10; 25(29):4557-61. PMID: 17876013.
      Citations: 156     Fields:    Translation:HumansCTClinical Trials
    211. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007 Sep 01; 13(17):5144-9. PMID: 17785569.
      Citations: 211     Fields:    Translation:HumansCTClinical Trials
    212. Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007 Jul 20; 25(21):3055-60. PMID: 17634483.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    213. Bickenbach K, Wilcox R, Veerapong J, Kindler HL, Posner MC, Noffsinger A, Roggin KK. A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J Gastrointest Surg. 2007 Jun; 11(6):758-66. PMID: 17417711.
      Citations: 7     Fields:    Translation:Humans
    214. Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):549-58. PMID: 17522864.
      Citations: 21     Fields:    Translation:HumansCells
    215. Kindler HL. Pancreatic cancer: an update. Curr Oncol Rep. 2007 May; 9(3):170-6. PMID: 17430687.
      Citations: 17     Fields:    Translation:Humans
    216. Vokes EE, Perry MC, Kindler HL, Green MR. The cancer and leukemia group B respiratory committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3581s-8s. PMID: 16740789.
      Citations: 1     Fields:    Translation:Humans
    217. Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, Hausner P, Kennedy R, Kindler H, Metintas M, Mutti L, Onda M, Pass H, Premkumar A, Roggli V, Sterman D, Sugarbaker P, Taub R, Verschraegen C. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol. 2006 Nov; 17(11):1615-9. PMID: 16600983.
      Citations: 21     Fields:    Translation:Humans
    218. Armato SG, Ogarek JL, Starkey A, Vogelzang NJ, Kindler HL, Kocherginsky M, MacMahon H. Variability in mesothelioma tumor response classification. AJR Am J Roentgenol. 2006 Apr; 186(4):1000-6. PMID: 16554570.
      Citations: 15     Fields:    Translation:Humans
    219. Oxnard GR, Armato SG, Kindler HL. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer. 2006 May; 52(2):141-8. PMID: 16530882.
      Citations: 16     Fields:    Translation:Humans
    220. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61. PMID: 16397249.
      Citations: 74     Fields:    Translation:HumansCells
    221. Shu KY, Kindler HL, Medenica M, Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol. 2006 Jan; 154(1):191-2. PMID: 16403122.
      Citations: 3     Fields:    Translation:Humans
    222. Kindler HL. Front-line therapy of advanced pancreatic cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S33-6. PMID: 16399428.
      Citations: 13     Fields:    Translation:Humans
    223. Dowell JE, Kindler HL. Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am. 2005 Dec; 19(6):1137-45, viii. PMID: 16325128.
      Citations: 9     Fields:    Translation:Humans
    224. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40. PMID: 16258101.
      Citations: 142     Fields:    Translation:HumansCTClinical Trials
    225. Kindler HL, Tothy PK, Wolff R, McCormack RA, Abbruzzese JL, Mani S, Wade-Oliver KT, Vokes EE. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs. 2005 Oct; 23(5):489-93. PMID: 16133801.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    226. Armato SG, Oxnard GR, Kocherginsky M, Vogelzang NJ, Kindler HL, MacMahon H. Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. Acad Radiol. 2005 Oct; 12(10):1301-9. PMID: 16179207.
      Citations: 11     Fields:    Translation:Humans
    227. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005 Oct; 16(10):1639-45. PMID: 16087696.
      Citations: 107     Fields:    Translation:HumansCTClinical Trials
    228. Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R, Tome MT, McKenna WJ, Lee P, Camici PG. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart. 2006 Mar; 92(3):357-60. PMID: 16085718; PMCID: PMC1860797.
      Citations: 58     Fields:    Translation:Humans
    229. Kindler HL, Friberg G, Skoog L, Wade-Oliver K, Vokes EE. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am J Clin Oncol. 2005 Aug; 28(4):340-4. PMID: 16062074.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    230. Kindler H, Bagger JP, Tait P, Camici PG. A vascular ring without compression: double aortic arch presenting as a coincidental finding during cardiac catheterisation. Heart. 2005 Jun; 91(6):773. PMID: 15894773; PMCID: PMC1768953.
      Citations: 3     Fields:    Translation:Humans
    231. Benson AB, Kindler HL, Jodrell D, Hagey A, Coates AI, Meek KA, Cernohous P, Gordon GB. Phase 2 study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC). J Clin Oncol. 2005 Jun; 23(16_suppl):3537. PMID: 27944407.
      Citations:    
    232. Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L, Janne P, Guterz TL, Stadler WM, Vokes EE. A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). J Clin Oncol. 2005 Jun; 23(16_suppl):7019. PMID: 27944450.
      Citations:    
    233. Simon GR, Janne PA, Langer CJ, Verschraegen CF, Dowlati A, Gadgeel SM, Kelly K, Taylor L, Obasaju CK, Kindler HL. A phase 2 clinical trial of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM). J Clin Oncol. 2005 Jun; 23(16_suppl):7235. PMID: 27944730.
      Citations:    
    234. Oxnard GR, Armato SG, Salgia R, Kindler HL. Development of response criteria for mesothelioma based on a mathematical model. J Clin Oncol. 2005 Jun; 23(16_suppl):7176. PMID: 27944992.
      Citations:    
    235. Friberg G, Kasza K, Vokes EE, Kindler HL. Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G). J Clin Oncol. 2005 Jun; 23(16_suppl):3020. PMID: 27945774.
      Citations:    
    236. Desai AA, Kindler HL, Taber D, Agamah E, Mani S, Wade-Oliver K, Ratain MJ, Vokes EE. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6. PMID: 15895230.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    237. Friberg G, Kindler HL. Chemotherapy for advanced pancreatic cancer: past, present, and future. Curr Oncol Rep. 2005 May; 7(3):186-95. PMID: 15847709.
      Citations: 3     Fields:    Translation:Humans
    238. Kindler HL. In focus: advanced pancreatic cancer. Clin Adv Hematol Oncol. 2005 May; 3(5):420-2. PMID: 16167016.
      Citations: 6     Fields:    Translation:Humans
    239. Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL, Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005 Mar 15; 11(6):2300-4. PMID: 15788680.
      Citations: 88     Fields:    Translation:HumansCTClinical Trials
    240. Kindler HL, Herndon JE, Zhang C, Green MR, Cancer and Leukemia Group B. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2005 Jun; 48(3):423-8. PMID: 15893012.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    241. Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N, Luhtala T, Boylan S, Dordal M, Robertson P, Hawkins MJ, Ratain MJ. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005 Jan; 23(1):31-7. PMID: 15528978.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    242. Eng C, Ramanathan RK, Ramathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT, Mani S, Kindler HL. A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol. 2004 Dec; 27(6):565-9. PMID: 15577433.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    243. Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA, Ratain MJ. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11. PMID: 15520075.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    244. Rudin CM, Marshall JL, Huang CH, Kindler HL, Zhang C, Kumar D, Gokhale PC, Steinberg J, Wanaski S, Kasid UN, Ratain MJ. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2004 Nov 01; 10(21):7244-51. PMID: 15534098.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    245. Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6111-8. PMID: 15447997.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    246. Kindler HL. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer. 2004 Aug; 45 Suppl 1:S125-7. PMID: 15261445.
      Citations: 10     Fields:    Translation:Humans
    247. Kindler HL, Avadhani A, Wade-Oliver K, Karrison T, Mani S, Vokes EE. 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs. 2004 Aug; 22(3):323-7. PMID: 15122080.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    248. Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H, Vokes E, MacEneany P, Mitchell MT, Stadler WM. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8. PMID: 15221817.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    249. Kindler HL. The emerging role of pemetrexed for the treatment of malignant mesothelioma. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):49-53. PMID: 15339060.
      Citations: 2     Fields:    Translation:Humans
    250. Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8. PMID: 15240523.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    251. Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, Humerickhouse R, Wang Q, Carr RA, Ratain MJ, André AK. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11. PMID: 15240529.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    252. Eng C, Kindler HL, Nattam S, Ansari RH, Kasza K, Wade-Oliver K, Vokes EE. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol. 2004 Jun; 15(6):928-32. PMID: 15151950.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    253. Armato SG, Oxnard GR, MacMahon H, Vogelzang NJ, Kindler HL, Kocherginsky M, Starkey A. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys. 2004 May; 31(5):1105-15. PMID: 15191298.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    254. Otterson GA, Herndon JE, Watson D, Green MR, Kindler HL, Cancer and Leukemia Group B. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer. 2004 May; 44(2):251-9. PMID: 15084390.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    255. Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol. 2003 Aug; 14(8):1270-3. PMID: 12881391.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    256. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6. PMID: 12733147.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    257. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003 Apr 15; 21(8):1556-61. PMID: 12697881.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    258. Kindler HL. Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec; 29(6 Suppl 18):49-53. PMID: 12571811.
      Citations: 2     Fields:    Translation:Humans
    259. Kindler HL. The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer. 2002 Aug 15; 95(4 Suppl):928-32. PMID: 12209673.
      Citations: 7     Fields:    Translation:Humans
    260. Kindler HL, de Gramont A. Pemetrexed in patients with gastrointestinal carcinoma. Semin Oncol. 2002 Apr; 29(2 Suppl 5):42-9. PMID: 12023792.
      Citations: 1     Fields:    Translation:Humans
    261. Mani S, Rudin CM, Kunkel K, Holmlund JT, Geary RS, Kindler HL, Dorr FA, Ratain MJ. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res. 2002 Apr; 8(4):1042-8. PMID: 11948111.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    262. Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 2002 Feb; 29(1):82-96. PMID: 11836673.
      Citations: 24     Fields:    Translation:HumansAnimals
    263. Kindler HL, van Meerbeeck JP. The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol. 2002 Feb; 29(1):70-6. PMID: 11836671.
      Citations: 9     Fields:    Translation:Humans
    264. Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7. PMID: 11786589.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    265. Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat Options Oncol. 2001 Dec; 2(6):459-71. PMID: 12057092.
      Citations: 30     Fields:    Translation:Humans
    266. Kosty MP, Herndon JE, Vogelzang NJ, Kindler HL, Green MR. High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. Lung Cancer. 2001 Nov; 34(2):289-95. PMID: 11679188.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    267. Eng C, Kindler HL, Schilsky RL. Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer. 2001 Aug; 1(2):95-103. PMID: 12445367.
      Citations: 3     Fields:    Translation:Humans
    268. Kindler HL, Millard F, Herndon JE, Vogelzang NJ, Suzuki Y, Green MR. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001 Feb-Mar; 31(2-3):311-7. PMID: 11165412.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    269. Kindler HL. Malignant pleural mesothelioma. Curr Treat Options Oncol. 2000 Oct; 1(4):313-26. PMID: 12057157.
      Citations: 5     Fields:    Translation:Humans
    270. Sandler AB, Kindler HL, Einhorn LH, Mitchell E, Masters G, Kraut M, Nicol S, Raghavan D. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol. 2000 Sep; 11(9):1161-4. PMID: 11061612.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    271. Schilsky RL, Kindler HL. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul; 9(7):1635-49. PMID: 11060767.
      Citations: 7     Fields:    Translation:HumansAnimals
    272. Kindler HL, Belani CP, Herndon JE, Vogelzang NJ, Suzuki Y, Green MR. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer. 1999 Nov 15; 86(10):1985-91. PMID: 10570422.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    273. Kindler H, Baranov AE, Fliedner TM, Mall H, Engelke A, Densow D. Internet-based physician's workbench as user interface for a central medical case repository. Methods Inf Med. 1999 Sep; 38(3):194-9. PMID: 10522123.
      Citations:    Fields:    Translation:HumansPHPublic Health
    274. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999 Jan 21; 340(3):190-5. PMID: 9917226.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    275. Kindler HL, Kris MG, Smith IE, Miller VA, Grant SC, Krebs JB, Ross GA, Slevin ML. Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. Am J Clin Oncol. 1998 Oct; 21(5):438-41. PMID: 9781595.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    276. Schwartz GN, Pendyala L, Kindler H, Meropol N, Perez R, Raghavan D, Creaven P. The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur J Cancer. 1998 Sep; 34(10):1543-8. PMID: 9893625.
      Citations: 3     Fields:    Translation:Humans
    277. Kindler H, Peter RU, Baranov AE, Fliedner TM, Densow D. Providing dermatological photographs using the multimedia extension of the international computer database for radiation accident case histories. Int J Med Inform. 1998 Jul; 51(1):39-50. PMID: 9749898.
      Citations:    Fields:    Translation:Humans
    278. Kindler H, Densow D, Fliedner TM. A pragmatic implementation of medical temporal reasoning for clinical medicine. Comput Biol Med. 1998 Mar; 28(2):105-20. PMID: 9684088.
      Citations:    Fields:    Translation:HumansPHPublic Health
    279. Kindler H, Densow D, Baranov AE, Fliedner TM, Peter RU. A multimedia database for dermatology. Stud Health Technol Inform. 1998; 52 Pt 1:70-4. PMID: 10384422.
      Citations: 1     Fields:    Translation:Humans
    280. Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R, Kris MG. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 1997 Dec; 8(12):1269-71. PMID: 9496394.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    281. Creaven PJ, Raghavan D, Pendyala L, Loewen G, Kindler HL, Berghorn EJ. Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-138-S12-143. PMID: 9331139.
      Citations: 2     Fields:    Translation:Humans
    282. Kindler H. Save medical personnel's time by improved user interfaces. Stud Health Technol Inform. 1997; 45:61-5. PMID: 10175373.
      Citations:    Fields:    Translation:Humans
    283. Densow D, Kindler H, Baranov AE, Tibken B, Hofer EP, Fliedner TM. Criteria for the selection of radiation accident victims for stem cell transplantation. Stem Cells. 1997; 15 Suppl 2:287-97. PMID: 9368315.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    284. Kindler H, Fliedner TM, Densow D. Internet access to a medical case repository for teaching and analysis. Proc AMIA Annu Fall Symp. 1997; 543-7. PMID: 9357685; PMCID: PMC2233561.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    285. Densow D, Kindler H. Necessity of extensive comprehensive databases for the improvement and test of diagnostic guidelines. Medinfo. 1995; 8 Pt 2:1055-8. PMID: 8591366.
      Citations:    Fields:    Translation:HumansPHPublic Health
    286. Kindler H, Densow D. A general hypertext-based explanation component for medical knowledge-based systems. Medinfo. 1995; 8 Pt 2:969-73. PMID: 8591602.
      Citations:    Fields:    Translation:HumansPHPublic Health
    287. Fliedner TM, Nothdurft W, Tibken B, Hofer E, Weiss M, Kindler H. Haemopoietic cell renewal in radiation fields. Adv Space Res. 1994 Oct; 14(10):541-54. PMID: 11539991.
      Citations:    Fields:    Translation:HumansAnimalsCells
    288. Bruno F, Kindler H, Leaning M, Moustakis V, Scherrer JR, Schreiber G, Stefanelli M. GAMES II Project: a general architecture for medical knowledge-based systems. Comput Methods Programs Biomed. 1994 Oct; 45(1-2):79-81. PMID: 7889771.
      Citations:    Fields:    
    289. Godfrey HP, Canfield LS, Kindler HL, Angadi CV, Tomasek JJ, Goodman JW. Production of a fibronectin-associated lymphokine by cloned mouse T cells. J Immunol. 1988 Sep 01; 141(5):1508-15. PMID: 3261752.
      Citations: 7     Fields:    Translation:AnimalsCells
    290. Scott D, Nitecki DE, Kindler H, Goodman JW. Immunogenicity of biotinylated hapten-avidin complexes. Mol Immunol. 1984 Nov; 21(11):1055-60. PMID: 6440008.
      Citations: 5     Fields:    Translation:AnimalsCells
    291. Kindler H. [Learning and teaching]. Z Krankenpfl. 1973 Aug-Sep; 66(9):324-5. PMID: 4491652.
      Citations:    Fields:    
    292. Brehme H, Dressler S, Kindler H, Kotlorz H, Linkenbach HJ, Tung LC, Waldschmitt J, Xanthakos D, Häring R, Kühn HG, De Peña Pérez R. [Arrangement of experiment for extracorporeal perfusion of pig's liver]. Med Welt. 1969 Jan 11; 2:82-5. PMID: 5765493.
      Citations: 2     Fields:    Translation:HumansAnimals
    293. Brehme H, Dressler S, Kindler H, Vaubel E, Linkenbach HJ, Matzen G, Tung LC, Waldschmidt J, Xanthakos D, Kühn HG, Häring R, De Pena Pérez R. [Results of experiments in homologous (swine-to-swine) extracorporeal perfusion]. Langenbecks Arch Chir. 1969; 325:1113-7. PMID: 5372311.
      Citations:    Fields:    Translation:Animals
    294. Kindler H. [Inhibitory effect of drugs on granulation tissue]. Hefte Unfallheilkd. 1969; 99:130-2. PMID: 5397429.
      Citations:    Fields:    Translation:Animals
    295. Waldschmidt J, Brehme H, Dressler S, Eckart J, Kindler H, Kotlorz H, Tung LC, Häring R, Kühn HG, De Pena Pérez R. [Treatment of hepatic coma by means of liver perfusion]. Langenbecks Arch Chir. 1969; 325:1123-8. PMID: 5392767.
      Citations:    Fields:    Translation:HumansAnimals
    296. Kindler H. [21. Inhibition of collagen fiber formation by cortisone]. Langenbecks Arch Chir. 1967; 319:162-5. PMID: 5587268.
      Citations: 1     Fields:    Translation:Animals
    297. KINDLER H. [AUTORADIOGRAPHIC STUDIES OF SKIN TRANSPLANTATION]. Langenbecks Arch Klin Chir Ver Dtsch Z Chir. 1964 Nov 17; 308:1001-3. PMID: 14347638.
      Citations:    Translation:Humans
    298. KINDLER H. [COMPARISON OF PROTEIN METABOLISM BETWEEN FIBROCYTES AND ACTIVATED FIBROBLASTS. (AUTORADIOGRAPHIC STUDIES WITH H3-LEUCINE)]. Klin Wochenschr. 1963 Nov 01; 41:1059-62. PMID: 14098340.
      Citations: 1     Fields:    Translation:AnimalsCells
    299. KINDLER H. [Autoradiographic studies on tissue protein metabolism in wound healing]. Klin Wochenschr. 1962 Jun 01; 40:601-2. PMID: 14456074.
      Citations:    Fields:    
    300. KINDLER H. [Paper electrophoresis in knee joint effusions]. Dtsch Med Wochenschr. 1959 Dec 04; 84:2192-5. PMID: 14409139.
      Citations: 2     Fields:    Translation:Humans
    301. KINDLER H, HALLENSCHEIDT F. [Treatment of severe forms of hematogenous osteomyelitis with special reference to protein metabolism]. Bruns Beitr Klin Chir. 1958 Jun; 196(4):464-75. PMID: 13560934.
      Citations:    Translation:Humans
    302. KINDLER H, KUEMMERLE HP. [Topical diagnosis of pheochromocytoma]. Fortschr Geb Rontgenstr Nuklearmed. 1956 Sep; 85(3):330-3. PMID: 13375746.
      Citations:    Fields:    Translation:Humans
    303. KUMMERLE F, KLOSS J, KINDLER H. [Treatment of the pleural empyema]. Dtsch Med Wochenschr. 1956 Jun 22; 81(25):1009-11. PMID: 13344051.
      Citations: 1     Fields:    Translation:Humans
    304. KINDLER H. [Surgical treatment of juvenile bone cysts and giant cell tumors]. Chirurg. 1955 Jan; 26(1):17-20. PMID: 14364698.
      Citations:    Fields:    Translation:Humans
    305. KINDLER H. [Specific tonicity of the muscles of the sole of the foot and the lower leg and its relation to foot deformities]. Z Orthop Ihre Grenzgeb. 1952; 81(4):607-13. PMID: 14951614.
      Citations: 1     Fields:    Translation:Humans
    306. KINDLER H. [Operative treatment of recurrent patellar dislocation]. Zentralbl Chir. 1951; 76(14):989-92. PMID: 14877277.
      Citations: 2     Fields:    Translation:Humans
    307. BAYER H, KINDLER H. [Effect of anemia upon the specific tonus of the voluntarily relaxed muscles]. Z Kreislaufforsch. 1950 May; 39(9-10):289-95. PMID: 15431855.
      Citations: 1     Fields:    Translation:Humans
    Kindler's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (787)
    Explore
    _
    Co-Authors (86)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _